These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Mansouri L; Noerenberg D; Young E; Mylonas E; Abdulla M; Frick M; Asmar F; Ljungström V; Schneider M; Yoshida K; Skaftason A; Pandzic T; Gonzalez B; Tasidou A; Waldhueter N; Rivas-Delgado A; Angelopoulou M; Ziepert M; Arends CM; Couronné L; Lenze D; Baldus CD; Bastard C; Okosun J; Fitzgibbon J; Dörken B; Drexler HG; Roos-Weil D; Schmitt CA; Munch-Petersen HD; Zenz T; Hansmann ML; Strefford JC; Enblad G; Bernard OA; Ralfkiaer E; Erlanson M; Korkolopoulou P; Hultdin M; Papadaki T; Grønbæk K; Lopez-Guillermo A; Ogawa S; Küppers R; Stamatopoulos K; Stavroyianni N; Kanellis G; Rosenwald A; Campo E; Amini RM; Ott G; Vassilakopoulos TP; Hummel M; Rosenquist R; Damm F Blood; 2016 Dec; 128(23):2666-2670. PubMed ID: 27670424 [TBL] [Abstract][Full Text] [Related]
4. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692 [TBL] [Abstract][Full Text] [Related]
5. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597 [TBL] [Abstract][Full Text] [Related]
12. NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways. Benedetti D; Tissino E; Pozzo F; Bittolo T; Caldana C; Perini C; Martorelli D; Bravin V; D'Agaro T; Rossi FM; Bomben R; Santinelli E; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Poeta G; Rossi D; Gaidano G; Dal Bo M; Gattei V; Zucchetto A Leukemia; 2018 Mar; 32(3):654-662. PubMed ID: 28935990 [TBL] [Abstract][Full Text] [Related]
13. NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia. Bonato A; Chakraborty S; Bomben R; Canarutto G; Felician G; Martines C; Zucchetto A; Pozzo F; Vujovikj M; Polesel J; Chiarenza A; Del Principe MI; Del Poeta G; D'Arena G; Marasca R; Tafuri A; Laurenti L; Piazza S; Dimovski AJ; Gattei V; Efremov DG Leukemia; 2024 Jul; 38(7):1511-1521. PubMed ID: 38486128 [TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Rodríguez A; Villuendas R; Yáñez L; Gómez ME; Díaz R; Pollán M; Hernández N; de la Cueva P; Marín MC; Swat A; Ruiz E; Cuadrado MA; Conde E; Lombardía L; Cifuentes F; Gonzalez M; García-Marco JA; Piris MA; Leukemia; 2007 Sep; 21(9):1984-91. PubMed ID: 17611561 [TBL] [Abstract][Full Text] [Related]
15. Responsiveness of chronic lymphocytic leukemia cells to B-cell receptor stimulation is associated with low expression of regulatory molecules of the nuclear factor-κB pathway. Meijers RWJ; Muggen AF; Leon LG; de Bie M; van Dongen JJM; Hendriks RW; Langerak AW Haematologica; 2020 Jan; 105(1):182-192. PubMed ID: 31097630 [TBL] [Abstract][Full Text] [Related]
16. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia. Sanchez-Lopez E; Ghia EM; Antonucci L; Sharma N; Rassenti LZ; Xu J; Sun B; Kipps TJ; Karin M Cell Death Differ; 2020 Jul; 27(7):2206-2216. PubMed ID: 31992855 [TBL] [Abstract][Full Text] [Related]
17. Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. Della-Valle V; Roos-Weil D; Scourzic L; Mouly E; Aid Z; Darwiche W; Lecluse Y; Damm F; Mémet S; Mercher T; Aoufouchi S; Nguyen-Khac F; Bernard OA; Ghamlouch H Blood Cancer J; 2020 Mar; 10(3):38. PubMed ID: 32170099 [TBL] [Abstract][Full Text] [Related]
18. Augmenting NF-κB in poor-risk CLL: A general paradigm for other cancers? Tuveson D; Rai KR J Exp Med; 2015 Jun; 212(6):830-1. PubMed ID: 26034117 [No Abstract] [Full Text] [Related]